Search

everythinglearnresearchcommunity

for

Search:↓

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.

Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

NF-κB signaling is crucial in many diseases and can be targeted for new treatments.

New treatments like JAK inhibitors show promise for reversing alopecia areata.

Apremilast did not work for treating severe alopecia areata.

Early genetic testing and JAK inhibitors can help treat systemic inflammation in SAVI patients.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.

Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.

Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.

Low dose methotrexate does not increase hair fall and may reduce it.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

Alopecia Areata is an autoimmune hair loss condition that needs more research for better treatments.

Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.

New treatments focusing on immune pathways show promise for stubborn hair loss.

Topical corticosteroids are the best initial treatment for children's alopecia areata.

Early treatment of Lupus Erythematosus Alopecia can prevent permanent hair loss, and various medications are effective.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

An elderly Chinese man lost all his hair after taking a new heart medication.

Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.

Upadacitinib may effectively treat alopecia areata without side effects.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.